172@29@17@106!~!172@29@0@53!~!|news|business|alembic-pharma-gets-eir-from-usfda-for-api-facility-at-karakhadi-5041741.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to PRO at just Rs.33 per month. Use code SUPERPRO
you are here: HomeNewsBusiness
Last Updated : Mar 17, 2020 12:54 PM IST | Source: PTI

Alembic Pharma gets EIR from USFDA for API facility at Karakhadi

"The company has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at our API facility at Karakhadi," the drug firm said in a filing to the BSE.

PTI
Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Alembic Pharmaceuticals on March 17 said that it has received an EIR from the US health regulator after inspection of its active pharmaceutical ingredient (API) facility at Karakhadi in Gujarat. The inspection was conducted during January 13-17.

"The company has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at our API facility at Karakhadi," the drug firm said in a filing to the BSE.

Shares of Alembic Pharma were trading at Rs 534.00 apiece on the BSE, up 0.55 percent from the previous close.
First Published on Mar 17, 2020 12:50 pm
Sections